| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-061 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 关于共同转债2025年付息的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、"共同转债"（债券代码：123171）将于 2025 年 11 月 28 日按面值支付第 三年利息，每 10 张"共同转债"（面值 1,000.00 元）利息为 11.00 元（含税）。 2、债权登记日：2025 年 11 月 27 日（星期四）； 3、除息日：2025 年 11 月 28 日（星期五）； 4、付息日：2025 年 11 月 28 日（星期五）； 5、本次付息期间及票面利率：计息期间为 2024 年 11 月 28 日至 2025 年 11 月 27 日，票面利率为 1.1%； 6、"共同转债"本次付息的债权登记日为 2025 年 11 月 27 日，截至 2025 年 11 月 27 日下午深圳证券交易所收市后，在中国证券登记结算有限责 ...

Core Viewpoint - The company reported a revenue increase of 24.54% year-on-year for the first three quarters of 2025, but also recorded a net loss attributable to shareholders of 32.43 million yuan [1] Financial Performance - The company's operating revenue for the first three quarters reached 455 million yuan [1] - The net loss attributable to shareholders was 32.43 million yuan [1] - The net loss after deducting non-recurring gains and losses was 32.21 million yuan [1] - The basic loss per share was 0.28 yuan [1]

Financial Performance - The company's revenue for Q3 2025 was ¥152,671,699.92, representing a 16.04% increase year-over-year, while the year-to-date revenue reached ¥455,071,340.26, up 24.54% compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2025 was -¥21,282,351.06, a decrease of 135.33% year-over-year, and the year-to-date net profit was -¥32,434,878.31, down 129.02% compared to the previous year[6] - The company reported a basic and diluted earnings per share of -¥0.1800 for Q3 2025, reflecting a decline of 130.77% year-over-year[6] - Total operating revenue increased to ¥455,071,340.26, up from ¥365,389,573.73, representing a growth of approximately 24.6% year-over-year[21] - Total operating costs rose to ¥505,144,105.05, compared to ¥407,868,913.77, reflecting an increase of about 24% year-over-year[21] - Net loss for the period was ¥37,430,322.36, worsening from a loss of ¥16,527,962.21 in the previous period[22] - Basic and diluted earnings per share for the current period were -0.28, compared to -0.12 in the previous period[23] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥2,856,762,745.40, an increase of 2.40% from the end of the previous year[6] - Total non-current assets reached ¥2,077,076,297.23, compared to ¥2,019,882,951.74, showing a growth of approximately 2.8%[18] - Total liabilities increased to ¥1,898,857,225.21 from ¥1,775,238,273.87, reflecting a rise of about 7%[19] - The company’s total equity attributable to shareholders decreased by 5.60% to ¥871,396,588.82 compared to the end of the previous year[6] Cash Flow - The net cash flow from operating activities for the first nine months of 2025 was -¥6,166,008.36, a decline of 106.61% compared to the previous year[12] - Cash inflow from operating activities totaled ¥412,169,849.05, a decrease from ¥489,936,789.49 in the previous period[23] - Cash outflow for investing activities was ¥141,243,927.94, significantly lower than ¥328,954,297.32 in the previous period[24] - Cash inflow from financing activities was ¥413,800,628.84, down from ¥610,668,158.75 in the previous period[24] - The ending balance of cash and cash equivalents was ¥81,374,902.32, slightly down from ¥81,618,387.68 in the previous period[24] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 14,193[14] - The largest shareholder, Xi Zubin, holds 31.72% of shares, totaling 36,567,000 shares[14] - The number of restricted shares held by Xi Zubin remains at 27,425,250 shares, with no changes during the period[16] - Li Minglei's restricted shares decreased from 11,528,250 to 10,293,975 shares after 1,234,275 shares were released[16] - There are no changes in the top 10 shareholders due to securities lending or borrowing activities[14] Research and Development - The company’s R&D expenses for the first nine months of 2025 were ¥51,357,520.12, a significant increase of 59.33% compared to ¥32,233,458.68 in the same period last year[11] - Research and development expenses increased significantly to ¥51,357,520.12 from ¥32,233,458.68, marking a rise of approximately 59.5% year-over-year[21] Financial Expenses - The company reported a 153.71% increase in financial expenses, amounting to ¥34,176,897.28, attributed to the cessation of capitalizing certain borrowing costs[11] - Financial expenses surged to ¥34,176,897.28, compared to ¥13,470,914.01, indicating a substantial increase of about 153% year-over-year[21] Other Financial Metrics - The company reported a significant increase in credit impairment losses, totaling ¥6,414,313.63, compared to a gain of ¥1,483,124.03 in the previous period[22] - The company did not undergo an audit for the third quarter financial report[25] - The company reported no net profit from the merged entity prior to the merger[23]

Financial Performance - In the first half of 2025, the company achieved operating revenue of 302 million CNY, representing a year-on-year increase of 29.33% compared to 233 million CNY in the same period last year [1][2] - The net profit attributable to shareholders was -11.15 million CNY, a decline of 117.88% from -5.12 million CNY in the previous year [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -10.22 million CNY, down 107.42% from -4.93 million CNY year-on-year [1][2] - The net cash flow from operating activities was -5.79 million CNY, a significant decrease of 116.98% from 34.11 million CNY in the same period last year [1][2] Previous Year Performance - In 2024, the company reported operating revenue of 537 million CNY, a decrease of 5.26% compared to the previous year [2] - The net profit attributable to shareholders was -27.59 million CNY, compared to a profit of 23 million CNY in the same period last year [2] - The net profit after deducting non-recurring gains and losses was -28.22 million CNY, down from a profit of 20.96 million CNY year-on-year [2] - The net cash flow from operating activities was -20.59 million CNY, compared to 68.13 million CNY in the previous year [2] Fundraising Activities - The company went public on the Shenzhen Stock Exchange's ChiNext board on April 9, 2021, issuing 29 million shares at a price of 8.24 CNY per share, raising a total of 238.96 million CNY [3] - The net proceeds from the public offering after deducting issuance costs were 194.18 million CNY, intended for production projects and working capital [3] - On December 13, 2022, the company announced the issuance of convertible bonds, raising a total of 380 million CNY, with net proceeds of 373.22 million CNY after costs [4] - The total amount raised from both fundraising activities was 618.96 million CNY [5]

Core Viewpoint - On October 17, 2025, the company announced the completion of its share repurchase plan, having repurchased a total of 1,069,600 shares, which represents 0.9278% of its current total share capital [1] Summary by Sections - **Share Repurchase Announcement** - The company initiated its share repurchase program on March 25, 2025, through a special securities account via centralized bidding [1] - The total number of shares repurchased is 1,069,600 [1] - This repurchase accounts for 0.9278% of the company's total share capital as of the announcement date [1]

Core Viewpoint - The company, Gongtong Pharmaceutical (300966.SZ), has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Group 1: Share Buyback Details - The company has repurchased a total of 1,069,600 shares, which represents 0.9278% of its current total share capital [1] - The highest transaction price during the buyback was 22.25 CNY per share, while the lowest was 13.15 CNY per share [1] - The total amount spent on the buyback was 21,969,816.00 CNY, excluding transaction fees [1]

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-059 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 关于回购公司股份进展暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开第 三届董事会第三次会议、第三届监事会第三次会议，审议通过了《关于回购公司股 份方案的议案》，同意公司使用自有资金及股票回购专项贷款资金以集中竞价交易 方式回购公司已发行的股份，用于股权激励或员工持股计划。本次回购总金额不低 于人民币 2,000 万元（含）且不超过人民币 3,000 万元（含），回购价格不超过 23.84 元/股，具体回购资金总额以回购期满时实际回购股份使用的资金总额为准，回购期 限为董事会审议通过该回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 2 月 20 日、2025 年 2 月 26 日在巨潮资讯网（www.cninfo.com.cn）上披 ...

Core Insights - The company is actively expanding its overseas market presence, with product exports projected to increase from 28.54% in 2024 to 38.6% by mid-2025 [2] - A joint venture with Huahai Pharmaceutical is focused on high-end steroid raw material production, with two production workshops already in trial production [3] - The company is leveraging synthetic biology technology to optimize processes and enhance customer collaboration in response to global pharmaceutical supply chain restructuring [5] Overseas Market Expansion and Future Plans - The company's export ratio is on the rise, with a target of 28.54% for 2024 and an increase to 38.6% by mid-2025 [2] - The company aims to strengthen brand promotion and sales channels through overseas subsidiaries and local partnerships [2] Raw Material Layout and Progress - The joint venture, Huahai Gongtong, aims to integrate strengths for high-end steroid raw material production, with plans divided into two phases covering 13 products [3] - Two production workshops are in trial production, with another set to begin soon, and preparations for registration documentation are underway [3] Applications of Steroid Products - Steroid drugs are categorized into sex hormones, progestogens, corticosteroids, and others, with applications in hormone replacement, disease treatment, and inflammation management [4] - The range of products and applications is continuously expanding [4] Response to Supply Chain Restructuring and Core Competitiveness - The global restructuring of the pharmaceutical supply chain is influencing the company's capacity layout and customer collaboration models [5] - The company views full supply chain collaboration as a core competitive advantage, enhancing efficiency across starting materials, intermediates, and raw materials [5] Plans for High-Value-Added Fields - Over the next 2-3 years, the company plans to extend into high-value-added areas, leveraging its complete industrial chain and professional R&D platform [6] - The focus will be on high-end intermediates and customized products [6]

Group 1: Company Overview and Market Expansion - The company's overseas market expansion has seen an increase in product export ratio from 28.54% in 2024 to 38.6% in the first half of 2025, indicating a consistent upward trend in international sales [2] - The primary overseas markets include Europe, North America, South America, and India [3] Group 2: Product Development and Production - The joint venture with Huahai Pharmaceutical focuses on high-end steroid raw materials, with a total of 13 high-end steroid raw material products planned, and two production workshops have entered trial production [3][4] - The company aims to enhance production efficiency and product quality by applying synthetic biology and other technologies [5] Group 3: Market Applications and Trends - Steroid drugs are categorized into sex hormones, progestogens, corticosteroids, and others, with applications in hormone replacement therapy, immune response treatment, and chronic disease management [4] - The restructuring of the global pharmaceutical supply chain presents new opportunities, particularly in reproductive health and chronic disease management for the aging population [5] Group 4: Competitive Strategy - The company emphasizes full supply chain collaboration as a core competitive advantage, focusing on optimizing raw material sourcing, intermediate production, and raw material drug development [5] - Plans to extend into high-value areas such as high-end intermediates and specialty raw materials are underway, supported by a complete industrial chain from steroid drug raw materials to intermediates and APIs [5]

Core Viewpoint - The company, Gongtong Pharmaceutical, has conducted a share buyback, acquiring a total of 968,400 shares, which represents 0.84% of its current total share capital, in compliance with relevant laws and its established buyback plan [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased shares through a special securities account via centralized bidding [1] - The highest transaction price was 22.25 CNY per share, while the lowest was 13.15 CNY per share [1] - The total amount spent on the buyback was 19,768,280.00 CNY, excluding transaction fees [1]